文献速递胸部肿瘤

国际肺癌研究协会提出的切除性非黏液性肺腺癌浸润病理学标准的临床意义

Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
PubMed 文献 · J Thorac Oncol · 2023-11-02

韩国三星医疗中心纳入2017年1月至2019年12月切除的部分实性肺腺癌患者1295例,用IASLC新浸润标准重新判定pT分期。再分期致22%降期、2.5%升期,与影像学及病理危险因素相关性改善,无复发生存区分(c指数0.794 vs 0.717)及复发或淋巴结转移预测(AUC 0.818 vs 0.741,p<0.001)均优于原pT分期。

要点

  • 按IASLC标准重新测量浸润成分后,22%降期、2.5%升期。
  • 修订pT与实性成分占比、最大标准化摄取值及病理危险因素的相关性改善。
  • 修订pT预测复发或淋巴结转移的AUC为0.818,原pT为0.741(p<0.001)。

核心结论

  • IASLC提出的浸润标准与临床病理危险因素更一致,预后判断能力更好。
  • 作者指出这是首个评估IASLC浸润标准临床意义的研究。
  • 作者认为仍需进一步研究评估IASLC标准对治疗决策和患者结局的影响。

研究设计与样本

  • 单中心研究,纳入韩国首尔三星医疗中心2017年1月至2019年12月切除的部分实性肺腺癌患者1295例。
  • 按IASLC标准新测量的浸润成分范围确定修订pT分期。
  • 主要结局为比较修订pT与原pT预测无复发生存及浸润证据(复发或淋巴结转移)的表现,次要结局为与影像学及病理危险因素的相关性。

主要发现

  • 重新评估导致pT降期22%、升期2.5%。
  • 修订pT区分无复发生存的c指数为0.794,原pT为0.717。
  • 修订pT预测复发或淋巴结转移的AUC为0.818,原pT为0.741(p<0.001)。
  • 修订pT与实性成分占比、最大标准化摄取值及病理危险因素的相关性改善。

关键数值与推荐

  • 修订pT区分无复发生存的c指数=0.794,原pT=0.717。
  • 修订pT预测复发或淋巴结转移的AUC=0.818,原pT=0.741(p<0.001)。
  • 再分期结果:降期22%,升期2.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为仍需进一步研究评估IASLC标准对治疗决策和患者结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Accurate diagnostic criteria for tumor invasion are essential for precise pathologic tumor (pT) staging. Recently, the International Association for the Study of Lung Cancer (IASLC) Pathology Committee suggested a new set of criteria for assessing tumor invasion, but the clinical usefulness of the proposed criteria has not been evaluated. METHODS: The study included 1295 patients with resected part-solid lung adenocarcinoma from January 2017 to December 2019 at the Samsung Medical Center, Seoul, Korea. The revised pT stage was determined by the extent of the newly measured invasive component using the IASLC criteria. The primary outcome was to compare the performance of the revised pT stage with the original pT stage in predicting recurrence-free survival and proof of invasion status (i.e., recurrence or lymph node metastasis). The secondary outcome was the correlation with radiologic surrogates of tumor invasiveness (consolidation-to-tumor ratio and maximum standardized uptake value) and pathologic risk factors. RESULTS: The re-evaluation resulted in a 22% downstaging and 2.5% upstaging of pT, which improved the correlation with radiologic (consolidation-to-tumor ratio and maximum standardized uptake value) and pathologic risk factors. The revised pT staging allowed for more accurate discrimination of recurrence-free survival than the original pT staging (c-index = 0.794 versus 0.717). Moreover, the revised pT staging significantly improved the prediction of recurrence or lymph node metastasis (area under the curve = 0.818 versus 0.741, p < 0.001). CONCLUSIONS: To our knowledge, this is the first study evaluating the clinical significance of the IASLC-proposed criteria for invasion. The proposed IASLC criteria offered better alignment with clinicopathologic risk factors and improved prognostication. Further studies are warranted to assess the impact of the IASLC criteria on treatment decisions and patient outcomes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hong TH, Hwang S, Cho J, et al. Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma. J Thorac Oncol. 2023. PMID: 37924973. doi:10.1016/j.jtho.2023.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。